ESC Congress 2026 Abstract · Oct 26, 2026

Prognosis and treatment response in cardiometabolic HFpEF: deep learning-based phenomapping with a pragmatic clinical classifier

By Wang T, Li R, Hua X et al.

Background and purpose: Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous syndrome. Although a cardiometabolic phenogroup is widely recognized, its clinical and prognostic implications remain unclear. We aimed to identify sub-phenotypes within cardiometabolic HFpEF, develop a simplified decision tool, compare their clinical characteristics, and evaluate their prognosis and treatment responses. Methods: We enrolled 1,158 hospitalized patients diagnosed with incident cardiometabolic HFpEF between April 2014 and December 2024. An unsupervised DeepCluster with a fully connected neural network was used to identify cardiometabolic HFpEF phenogroups. We assessed feature importance using random forest Gini impurity score and SHapley Additive exPlanations (SHAP), then derived a classification tree (CART) based on the top 15 non-collinear features. Clinical characteristics were compared across identified phenogroups. All-cause mortality, heart failure rehospitalization, and treatment responses were evaluated using multivariable Cox proportional hazards models. Results: Two distinct phenogroups among cardiometabolic HFpEF patients (Figure 1A) were identified based on 87 demographic and echocardiographic variables, clinical biomarkers, medical and medication history. Phenogroup 1 (n = 356) showed more severe symptoms and diastolic dysfunction, higher disease burden of diabetes and chronic kidney disease, and elevated levels of NT-proBNP, US-CRP, cTnT, uric acid, Urea, creatinine, glucose, and HbA1c (Figure 1B-D). Phenogroup 2 (n = 802) had higher prevalence of hyperlipidemia and more frequent usage of SGLT2 inhibitor, statin, cholesterol-absorption inhibitors, and metformin. For prognostic outcomes, phenogroup 1 had significantly higher all-cause mortality than phenogroup 2 (HR=5.19, 95%CI: 3.04-8.86, Figure 1E). Statin use (HR = 0.55, 95% CI 0.35-0.86) and metformin (HR = 0.19, 95% CI 0.05-0.78) showed significant protective effects overall. Antiplatelet medication use had a significant treatment-by-phenogroup interaction. It was significantly associated with lower all-cause mortality in phenogroup 2 (HR=0.26, 95%CI: 0.10-0.67, p-interaction=0.004). We derived a simplified CART classifier based on NT-proBNP, E/e’, and left atrial diameter that well discriminated the phenogroups (macro F1-score=0.844, Figure 1F). Conclusion: Our DeepCluster model identified two distinct cardiometabolic HFpEF phenogroups. The high-risk group was characterized by more severe diastolic dysfunctions and a greater cardiovascular-kidney-metabolic burden. The derived phenomapping classifier may support a pragmatic risk stratification and inform individualized treatment in cardiometabolic HFpEF.

doi.org/10.1093/eurheartj/ehag785.1132Open accessBiomarkers

AgingResearch.News